Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT LEXICON PHARMACEUTICALS, INC.

Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX)
Listen to this Section


$2.23
+0.0650 ( +3.01% ) 1.9M

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.

Clinical Trial Pipeline Stages


Drug Name Stage
INPEFA™ (SOTAGLIFLOZIN)DetailsHeart disease, Heart failure Approved
XERMELO® (telotristat ethyl)DetailsCarcinoid syndrome diarrhea Approved
ZYNQUISTA™ (sotagliflozin)DetailsHypertrophic cardiomyopathies Phase 3
LX9211DetailsNeuropathy, Diabetic peripheral neuropathy Phase 2b
ZYNQUISTA™ (sotagliflozin)DetailsType 1 diabetes, Diabetes Failed

Market Data


Open $2.23
Previous Close $2.16
Volume 1.9M
Market Cap $959.46M
Day Range $2.14 - $2.27
52 Week Range $0.73 - $2.53
Shares Outstanding 444.20M
Change % +3.01%
Net Change ▲ 0.0650
Insider Ownership -0.06%
Exchange NASDAQ
SectorHealthcare
IndustryBiotechnology
IPO Year2000
CountryUnited States

Insider Ownership Transactions

Total Amount Purchased: -63,152,917.00

Date Type Amount Purchased Purchaser
2024-02-29 Sale -18944.00 McDermott Wendy
2024-02-29 Sale -8977.00 MAIN ALAN J
2024-02-29 Sale -7087.00 Kassler-Taub Kenneth B.
2024-02-29 Sale -27916.00 Granowitz Craig B
2024-02-29 Sale -8750.00 Crum Brian T
2024-02-29 Sale -33333.00 COATS LONNEL
2024-02-12 Sale -222680.00 Granowitz Craig B
2024-02-12 Sale -227130.00 Garner Thomas
2024-02-12 Sale -208160.00 Crum Brian T
2024-02-12 Sale -203810.00 Kassler-Taub Kenneth B.

SEC Filings


Form Type Description Pages Date
8-k 8K-related 12 Nov 10, 2025
10-q Quarterly Reports 57 Nov 06, 2025
8-k 8K-related 15 Nov 06, 2025
8-k 8K-related 13 Nov 06, 2025
10-q Quarterly Reports 57 Aug 06, 2025
8-k 8K-related 13 Aug 06, 2025
8-k 8K-related 12 Jul 28, 2025
8-k 8K-related 12 Jul 03, 2025
3 Insider transactions 1 Jun 09, 2025
3 Insider transactions 1 Jun 06, 2025

Latest News